Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Arcuri R, Abbolito M R, Greiner J W, Schlom J
Regina Elena Cancer Institute, Rome, Italy.
Dis Colon Rectum. 1994 Feb;37(2 Suppl):S16-23. doi: 10.1007/BF02048426.
Tumor-associated glycoprotein-72 has been recently suggested as a new serum marker for colorectal cancer. In fact, approximately 40 percent of colorectal cancer patients have positive tumor-associated glycoprotein-72 serum levels at the time of diagnosis, while only 3 percent of patients with benign diseases are positive. A longitudinal evaluation of colorectal cancer patients suggested the utility of combining the measurement of tumor-associated glycoprotein-72 with that of carcinoembryonic antigen to monitor disease status not only at the time of diagnosis, but also at the time of recurrence. Several reports have indicated that the expression of some tumor antigens in colorectal adenomas may correlate with those parameters conventionally considered as indicative of malignant transformation. The presence of tumor-associated glycoprotein-72 in colorectal adenomas has been recently correlated with preneoplastic lesions, suggesting that tumor-associated glycoprotein-72 may be considered as an early marker of neoplastic transformation. The evaluation of tumor antigens can be considered a new tool in the management of colorectal cancer.
肿瘤相关糖蛋白-72最近被认为是一种新的结直肠癌血清标志物。事实上，约40%的结直肠癌患者在诊断时肿瘤相关糖蛋白-72血清水平呈阳性，而良性疾病患者只有3%呈阳性。对结直肠癌患者的纵向评估表明，将肿瘤相关糖蛋白-72的检测与癌胚抗原的检测相结合，不仅在诊断时，而且在复发时，都有助于监测疾病状态。几项报告表明，结直肠腺瘤中某些肿瘤抗原的表达可能与那些传统上被认为指示恶性转化的参数相关。结直肠腺瘤中肿瘤相关糖蛋白-72的存在最近已与癌前病变相关联，这表明肿瘤相关糖蛋白-72可被视为肿瘤转化的早期标志物。肿瘤抗原的评估可被视为结直肠癌管理中的一种新工具。
